Pediatric Multiple Sclerosis

Pediatric multiple sclerosis (MS), also called juvenile MS, refers to early-onset multiple sclerosis that affects children as young as age 4 or 5.

It is estimated that around 10,000 children worldwide have pediatric MS. Exact numbers are difficult to ascertain, however, as the symptoms of pediatric MS overlap with those of several other conditions.

Symptoms of pediatric MS

Children with MS exclusively have relapsing-remitting multiple sclerosis (RRMS). That is, they have symptomatic periods (relapse) followed by almost complete recovery (remission), in which they have only a few symptoms or none at all. These symptoms are similar to those seen in adults and may include fatigue, numbness or tingling, muscle spasms or weakness, walking difficulties, bladder or bowel problems, vision problems, and emotional changes.

While children with MS tend to have more relapses than adults, they also tend to recover more quickly during remission. Pediatric MS seems to affect girls more than boys, which may indicate that hormones modify disease progression.

Diagnosis of pediatric MS

Diagnosing pediatric MS is challenging because there are few criteria to diagnose the disease in children. Moreover, the symptoms of pediatric MS may be confused with those of acute disseminated encephalomyelitis or other pediatric diseases.

Children with MS also have fewer brain lesions visible in magnetic resonance imaging (MRI) scans, making diagnosis harder.

In general, a child must have two discrete demyelinating events — these include inflammation, vision loss, tremors, and muscle spasms — to be diagnosed with pediatric MS.

Treatment of pediatric MS

Very few controlled clinical trials have been carried out in children with MS to test disease-modifying therapies because of the limited number of patients.

Children with MS are generally treated with adult therapies such as interferon beta and glatiramer acetate but the tolerability and effect of these treatments in juvenile patients are not well-known.

Gilenya (fingolimod) is one MS treatment that has been tested and approved in patients with MS, ages 10 and older.


Last updated: Jan. 8, 2020


Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here